506 related articles for article (PubMed ID: 31243259)
41. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
[TBL] [Abstract][Full Text] [Related]
43. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
44. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
45. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
Gülfe A; Wallman JK; Kristensen LE
Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
[TBL] [Abstract][Full Text] [Related]
46. Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis.
Truffot A; Gautier-Veyret E; Baillet A; Jourdil JF; Stanke-Labesque F; Gottenberg JE
Fundam Clin Pharmacol; 2021 Dec; 35(6):1090-1099. PubMed ID: 33638167
[TBL] [Abstract][Full Text] [Related]
47. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R; Cho SK; Nanki T; Watanabe K; Yamazaki H; Tanaka M; Koike R; Tanaka Y; Saito K; Hirata S; Amano K; Nagasawa H; Sumida T; Hayashi T; Sugihara T; Dobashi H; Yasuda S; Sawada T; Ezawa K; Ueda A; Fujii T; Migita K; Miyasaka N; Harigai M;
Arthritis Res Ther; 2015 Mar; 17(1):74. PubMed ID: 25880658
[TBL] [Abstract][Full Text] [Related]
48. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
49. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
[TBL] [Abstract][Full Text] [Related]
50. Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
Reams J; Berger A; Denio A
Medicine (Baltimore); 2020 Aug; 99(35):e21827. PubMed ID: 32871905
[TBL] [Abstract][Full Text] [Related]
51. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
[TBL] [Abstract][Full Text] [Related]
52. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.
Karadag O; Farisogullari B; Yagiz B; Erden A; Ademoglu Z; Kimyon G; Bilge NS; Icacan OC; Kilic L; Coskun BN; Ersozlu ED; Kucuksahin O; Mercan R; Koca SS; Gonullu E; Cinar M; Akar S; Emmungil H; Kasifoglu T; Bes C; Omma A; Pehlivan Y; Kiraz S; Ertenli I; Dalkilic E; Kalyoncu U
Clin Exp Rheumatol; 2024 Jan; 42(1):130-137. PubMed ID: 37650346
[TBL] [Abstract][Full Text] [Related]
53. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis.
Melville AR; Md Yusof MY; Fitton J; Garcia-Montoya L; Bailey L; Dass S; Emery P; Buch MH; Saleem B
Rheumatology (Oxford); 2021 Aug; 60(8):3679-3688. PubMed ID: 33432358
[TBL] [Abstract][Full Text] [Related]
54. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
55. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
[TBL] [Abstract][Full Text] [Related]
56. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis.
Pers YM; Schaub R; Constant E; Lambert J; Godfrin-Valnet M; Fortunet C; Bourichi W; Prades BP; Wendling D; Gaudin P; Jorgensen C; Maillefert JF; Marotte H
Joint Bone Spine; 2015 Jan; 82(1):25-30. PubMed ID: 25241333
[TBL] [Abstract][Full Text] [Related]
58. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
59. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
Paul D; Patil D; McDonald L; Patel V; Lobo F
J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
[No Abstract] [Full Text] [Related]
60. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
